Biliary Tract Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Cholangiocarcinoma (181)

Gallbladder Cancer (41)

Cholangiocarcinoma (181)

Gallbladder Cancer (41)

›

HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 3 days (New C3) BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 3d	BI 1810631 Sensitive: C3 – Early Trials IASLC-TTLC 2023 - 3 days BI 1810631 Sensitive : C3 IASLC-TTLC 2023 - 3 days - (New C3)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 6 days (New B) pembrolizumab Sensitive : B Merck (MSD) Press Release - 6d	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 6 days pembrolizumab Sensitive : B Merck (MSD) Press Release - 6 days - (New B)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week (New C3) futibatinib Sensitive : A1 N Engl J Med - 1wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week futibatinib Sensitive : A1 N Engl J Med - 1 week - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week (New C3) futibatinib Sensitive : A1 N Engl J Med - 1wk	futibatinib Sensitive: A1 - Approval N Engl J Med - 1 week futibatinib Sensitive : A1 N Engl J Med - 1 week - (New C3)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 1 week (New C4) palbociclib Sensitive : C4 Onco Targets Ther - 1wk	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 1 week palbociclib Sensitive : C4 Onco Targets Ther - 1 week - (New C4)
CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	CAPZA2-MET fusion + MET amplification	Cholangiocarcinoma	capmatinib Sensitive: C4 – Case Studies The Oncologist - 1 week (New C4) capmatinib Sensitive : C4 The Oncologist - 1wk	capmatinib Sensitive: C4 – Case Studies The Oncologist - 1 week capmatinib Sensitive : C4 The Oncologist - 1 week - (New C4)
PD-L1 expression	Biliary Tract Cancer	PD-L1 expression	Biliary Tract Cancer	nivolumab Sensitive: C1 - Off-label ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C1 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C1 - Off-label ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C1 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C2 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Cholangiocarcinoma	MDM2 amplification	Cholangiocarcinoma	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification	Biliary Tract Cancer	MDM2 amplification	Biliary Tract Cancer	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) BI 907828 Sensitive : C2 ASCO-GI 2023 - 2wk	BI 907828 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks BI 907828 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C2 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation	Cholangiocarcinoma	FGFR mutation	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) erdafitinib Sensitive : C3 ASCO-GI 2023 - 2wk	erdafitinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks erdafitinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ICP-192 Sensitive : C3 ASCO-GI 2023 - 2wk	ICP-192 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ICP-192 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Biliary Tract Cancer	KRAS mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) TT-00420 Sensitive : C3 ASCO-GI 2023 - 2wk	TT-00420 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks TT-00420 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	GC Sensitive: A2 - Guideline GC Sensitive : A2	GC Sensitive: A2 - Guideline GC Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	GEM-CAP Sensitive: A2 - Guideline GEM-CAP Sensitive : A2	GEM-CAP Sensitive: A2 - Guideline GEM-CAP Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	FP Sensitive: A2 - Guideline FP Sensitive : A2	FP Sensitive: A2 - Guideline FP Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	XP Sensitive: A2 - Guideline XP Sensitive : A2	XP Sensitive: A2 - Guideline XP Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	FP Sensitive: A2 - Guideline FP Sensitive : A2	FP Sensitive: A2 - Guideline FP Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	XP Sensitive: A2 - Guideline XP Sensitive : A2	XP Sensitive: A2 - Guideline XP Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2
BRAF V600E	Biliary Tract Cancer	BRAF V600E	Biliary Tract Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
NTRK3 fusion	Biliary Tract Cancer	NTRK3 fusion	Biliary Tract Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Biliary Tract Cancer	NTRK2 fusion	Biliary Tract Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Biliary Tract Cancer	NTRK3 fusion	Biliary Tract Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Biliary Tract Cancer	NTRK2 fusion	Biliary Tract Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2

Biliary Tract Cancer

Associations(321)

Associations
(321)